C
Cees J. Tack
Researcher at Radboud University Nijmegen
Publications - 249
Citations - 9552
Cees J. Tack is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Diabetes mellitus & Insulin. The author has an hindex of 46, co-authored 234 publications receiving 8262 citations. Previous affiliations of Cees J. Tack include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
The Inflammasome and Caspase-1 Activation: A New Mechanism Underlying Increased Inflammatory Activity in Human Visceral Adipose Tissue
Tim B. Koenen,Rinke Stienstra,Rinke Stienstra,Lambertus J.H. van Tits,Leo A. B. Joosten,Jeroen F. van Velzen,Anneke Hijmans,Jillis A. Pol,J.A. van der Vliet,Mihai G. Netea,Cees J. Tack,Anton F. H. Stalenhoef,Jacqueline de Graaf +12 more
TL;DR: The results show that caspase-1 and nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 inflammasome members are abundantly present in human VAT and represents a novel and specific inflammatory pathway that may determine the proinflammatory character of this specific depot.
Journal ArticleDOI
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity
Rinke Stienstra,Leo A. B. Joosten,Tim B. Koenen,Jos W. M. van der Meer,Cees J. Tack,Thirumala D. Kanneganti,Mihai G. Netea +6 more
Journal ArticleDOI
Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients
Hanneke Boon,Marlies Bosselaar,Stephan F. E. Praet,Ellen E. Blaak,W. H. M. Saris,Anton J. M. Wagenmakers,Sean L. McGee,Cees J. Tack,Paul Smits,Mark Hargreaves,L.J.C. van Loon +10 more
TL;DR: The i.v. administration of AICAR reduces hepatic glucose output, thereby lowering blood glucose concentrations in vivo in type 2 diabetic patients, and stimulates hepatic fatty acid oxidation and/or inhibits whole body lipolysis, thereby reducing plasma NEFA concentration.
Journal ArticleDOI
A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
Tim Heise,Cees J. Tack,Robert M. Cuddihy,Jaime A. Davidson,Didier Gouet,Andreas Liebl,Enrique Romero,Henriette Mersebach,Patrik Dykiel,Rolf Jorde +9 more
TL;DR: In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control.
Journal ArticleDOI
Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology
TL;DR: Administration of insulin aspart by jet injection enhances insulin absorption and reduces the duration of glucose-lowering action and may help to achieve better meal insulin coverage and correction of postprandial glucose excursions.